CNS Pharmaceuticals, Inc., (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco , CEO of CNS Pharmaceuticals, will present at the Life Sciences Investor Forum being
HOUSTON, June 23, 2020 /PRNewswire/ -- CNS PHARMACEUTICALS AG, Inc., (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the Life Sciences Investor Forum being held virtually on June 25th, 2020 at 12:30pm ET. Details of the presentation are below:
This will be an interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register for the event using the following link: https://www.lifesciencesinvestorforum.com/login-registration. Learn more about the event at www.lifesciencesinvestorforum.com. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has been shown in preclinical studies to be 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com. Forward-Looking Statements View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-to-present-at-the-life-sciences-investor-forum-301081618.html SOURCE CNS Pharmaceuticals, Inc. | ||||||||||
Company Codes: NASDAQ-NMS:CNSP |